Report Library
All Reports
Breast Cancer KOL Insight Interview
May 08, 2014
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2014
for purchase a la carte, or access to all reports and surveys can be purchased as a
subscription to KOL Insight. For more information on KOL Insight subscription, please
email BioMedTracker
or call BioMedTracker Client Services at (858) 200-2357.
KOL Highlights Include:
For our disclosures, please read the BioMedTracker Research Standards.
KOL Highlights Include:
- Physicians are starting to use Perjeta (Roche) as an add-on to Herceptin in the adjuvant setting due to a recent change in NCCN (National Comprehensive Cancer Network, an alliance of major cancer centers) guidelines.
- Tykerb (lapatinib, NVS) has poor efficacy relative to Kadcyla (Roche) in HER2-positive patients, and results from studies attempting to expand Tykerb usage to different or earlier lines of therapy have not been impressive.
- Neratinib (PBYI) would need to be better than Kadcyla to garner significant usage in the metastatic setting.
- Kadcyla tolerability is probably better than Herceptin + chemotherapy, so favorable results in studies of Kadcyla in early breast cancer could increase Kadcyla usage.
- This oncologist’s practice does not use Avastin (Roche) despite its presence in the NCCN guidelines, partly due to the lack of OS benefit.
- MammaPrint (Agendia) sometimes gives results that are difficult to interpret and discordant with information generated by Oncotype (Genomic Health, Inc.) and information from this oncologist’s expertise.
- Public awareness has led to an increase in BRCA screening, and BRCA screening would increase further if a PARP inhibitor with a BRCA-mutation population in its label were approved.
- Preliminary results from palbociclib (PFE) are favorable and exciting, and this physician would give letrozole+palbociclib to most eligible patients.
- Past results for therapeutic vaccines for breast cancer do not give this oncologist optimism for the field.
- Halaven (ESALY) has good efficacy as a single-agent cytotoxic in advanced breast cancer.
For our disclosures, please read the BioMedTracker Research Standards.
| Indications Covered: | Breast Cancer |
Additional Resources: